Alvotech Adopts ³Ô¹Ï±¬ÁÏ Vault Training
to Simplify Role-Based Qualifications and Training
Specialty biopharmaceutical company can easily organize, assign, and track training
for improved audit-readiness and compliance
PLEASANTON, CA ¡ª May 18, 2020 ¡ª ³Ô¹Ï±¬ÁÏ Systems (NYSE:VEEV) today announced that Alvotech, a biopharmaceutical company specializing in biosimilars, adopted ³Ô¹Ï±¬ÁÏ Vault Training for more effective role-based training across its organization. With Vault Training, Alvotech can easily assign and track training tasks based on specific job functions or roles to remain audit ready and compliant within Europe.
The addition of Vault Training builds upon the company's success with Vault QMS and Vault QualityDocs, giving Alvotech a suite of advanced quality, document, and training management applications to automate and harmonize quality processes globally.
¡°We deployed ³Ô¹Ï±¬ÁÏ Vault Training in only four months from project kick-off to full migration of all legacy training records, and were immediately training people, tracking completion, and monitoring qualification status,¡± said Gudmundur Oskarsson, chief information officer at Alvotech. ¡°We¡¯re pleased to be among the first companies to implement Vault Training in Europe. Together with ³Ô¹Ï±¬ÁÏ Vault QMS and ³Ô¹Ï±¬ÁÏ Vault QualityDocs, we can now seamlessly bring together quality processes, content, and training.¡±
Alvotech is a fast-growing company that needed an effective way to manage and verify the right people are trained and current on the latest quality policies and procedures. Since April 2020, Alvotech has distributed more than 16,000 new training assignments with Vault Training. Combined with Vault QualityDocs and Vault QMS, quality teams can provide individuals easy content access to complete training tasks, as well as have complete traceability of new training requirements.
¡°³Ô¹Ï±¬ÁÏ enables Alvotech to modernize quality processes, document control, and training to drive greater speed and efficiency throughout its operations,¡± said Robert Gaertner, senior director of strategy for ³Ô¹Ï±¬ÁÏ Vault Quality. ¡°We¡¯re proud to continue our strategic partnership with Alvotech and help its teams effectively manage and deliver training for improved compliance and audit-readiness.¡±
Vault Training, Vault QMS, and Vault QualityDocs are part of ³Ô¹Ï±¬ÁÏ Vault Quality Suite, helping organizations streamline business processes across global sites, suppliers, contract manufacturers, and partners to speed workflows for greater efficiency.
Learn how Vault Quality Suite is enabling organizations to modernize quality management at the upcoming online ³Ô¹Ï±¬ÁÏ R&D Summit, May 19-20, 2020. The virtual event is open to ³Ô¹Ï±¬ÁÏ customers and invited guests. Register and view the agenda at veeva.com/EUSummit.
Additional Information
For more on ³Ô¹Ï±¬ÁÏ Vault Training, visit: veeva.com/VaultTraining
Connect with ³Ô¹Ï±¬ÁÏ on LinkedIn:
Follow @veevasystems on Twitter:
Like ³Ô¹Ï±¬ÁÏ on Facebook:
About Alvotech
Alvotech is a multinational biopharmaceutical company focused on the development and manufacture of high quality biosimilars for global markets. We are specialists in biotechnology, seeking to be a global leader in the biosimilar space by delivering high quality, cost-competitive products and services to our partners and to patients worldwide. Our fully integrated approach, with high-quality in-house competencies throughout the value chain, enables the accelerated development of biosimilar products. Alvotech¡®s initial pipeline contains several monoclonal-antibody and fusion-protein biosimilar candidates aimed at treating autoimmunity, oncology and inflammatory conditions to improve quality of life for patients around the world. For more information, please visit our website, or follow us on , and .
About ³Ô¹Ï±¬ÁÏ Systems
³Ô¹Ï±¬ÁÏ Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, ³Ô¹Ï±¬ÁÏ serves more than 850 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. ³Ô¹Ï±¬ÁÏ is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of ³Ô¹Ï±¬ÁÏ¡¯s products and services, the results from use of ³Ô¹Ï±¬ÁÏ¡¯s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon ³Ô¹Ï±¬ÁÏ¡¯s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent ³Ô¹Ï±¬ÁÏ¡¯s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and ³Ô¹Ï±¬ÁÏ disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect ³Ô¹Ï±¬ÁÏ¡¯s financial results are included under the captions, ¡°Risk Factors¡± and ¡°Management¡¯s Discussion and Analysis of Financial Condition and Results of Operations,¡± in the company¡¯s filing on Form 10-K for the period ended January 31, 2020. This is available on the company¡¯s website at veeva.com under the Investors section and on the SEC¡¯s website at . Further information on potential risks that could affect actual results will be included in other filings ³Ô¹Ï±¬ÁÏ makes with the SEC from time to time.
###
Contact:
³Ô¹Ï±¬ÁÏ Systems
pr@veeva.com
Deivis Mercado
³Ô¹Ï±¬ÁÏ Systems
925-226-8821
deivis.mercado@veeva.com